Burning Rock Biotech Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Yusheng Han

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	16.9%
Durchschnittliche Amtszeit des Managements	8.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.4yrs

Jüngste Management Updates

Recent updates

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 12

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Apr 28

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Dec 23

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Sep 20

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Aug 31

Burning Rock Localizes As Investors Grow Impatient

Jun 06

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Mar 24

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Nov 17

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

Aug 27

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Jul 23

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

May 13

Burning Rock Biotech Expands Test Portfolio In Bid For Growth

Dec 30

Burning Rock inks license pact with Oncocyte Corporation

Dec 15

Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS

Dec 04

Burning Rock Biotech EPS misses by $0.08, beats on revenue

Nov 20

Geschäftsführer

Yusheng Han (45 yo)

no data

Amtszeit

Mr. Yusheng Han is the Founder, Chairman and chief executive officer of Burning Rock Biotech Limited. Mr. Han has 16 year of experience in life science. From June 2011 to November 2013, he was an associate...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yusheng Han	Founder	no data	keine Daten	16.92% $ 9.3m
Xiaozhi Hu	Senior Director of Finance	less than a year	keine Daten	keine Daten
Zhihong Zhang	CTO & Director	8.7yrs	keine Daten	keine Daten
Hao Liu	Senior Advisor	9.3yrs	keine Daten	keine Daten

8.7yrs

Durchschnittliche Betriebszugehörigkeit

48yo

Durchschnittliches Alter

Erfahrenes Management: BNRDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.7 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yusheng Han	Founder	no data	keine Daten	16.92% $ 9.3m
Zhihong Zhang	CTO & Director	1.4yrs	keine Daten	keine Daten
Feng Deng	Director	8.3yrs	keine Daten	keine Daten
Gang Lu	Director	10.4yrs	keine Daten	keine Daten
Wendy Hayes	Independent Director	4.4yrs	keine Daten	keine Daten
Licen Lisa Xu	Independent Director	2.4yrs	keine Daten	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

53yo

Durchschnittliches Alter

Erfahrener Vorstand: BNRDie Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).

Burning Rock Biotech Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Burning Rock Biotech Limited Announces the Resignation of Leo Li as Chief Financial Officer

Burning Rock Biotech Limited, Annual General Meeting, Dec 20, 2023

Burning Rock Biotech Limited Announces Management Changes, Effective June 30, 2023

Less than half of directors are independent

Burning Rock Biotech Limited, Annual General Meeting, Sep 08, 2022

Burning Rock Biotech Limited Announces Board Changes

Recent updates

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Burning Rock Biotech Limited Announces the Resignation of Leo Li as Chief Financial Officer

Burning Rock Biotech Announces Expected Delisting of American Depositary Shares

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Burning Rock Biotech Limited to Report Q1, 2024 Results on May 29, 2024

New minor risk - Shareholder dilution

Full year 2023 earnings released: CN¥6.38 loss per share (vs CN¥9.35 loss in FY 2022)

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

New minor risk - Share price stability

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

New major risk - Financial position

Burning Rock Announces Receipt of Notification from NASDAQ

Third quarter 2023 earnings released: CN¥1.71 loss per share (vs CN¥2.23 loss in 3Q 2022)

Burning Rock Biotech Limited, Annual General Meeting, Dec 20, 2023

Burning Rock Biotech Limited to Report Q3, 2023 Results on Nov 30, 2023

Burning Rock Biotech Limited Receives Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Second quarter 2023 earnings released: CN¥1.54 loss per share (vs CN¥2.50 loss in 2Q 2022)

New minor risk - Share price stability

Burning Rock Biotech Limited to Report Q2, 2023 Results on Aug 31, 2023

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Burning Rock Biotech Limited Announces Management Changes, Effective June 30, 2023

Burning Rock Biotech Limited Reiterates Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: CN¥1.81 loss per share (vs CN¥2.50 loss in 1Q 2022)

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Burning Rock Biotech Limited Revises Revenue Guidance for Full Year of 2022

Burning Rock Biotech Limited Revises Revenue Guidance for Full Year of 2022

Burning Rock Received FDA Breakthrough Device Designation for Its Overc(Tm) Multi-Cancer Detection Blood Test

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Consensus revenue estimates fall by 13%

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Burning Rock Biotech Limited Provides Earnings Guidance for the Fourth Quarter and Year of 2022

Less than half of directors are independent

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Burning Rock Biotech Limited to Report Q3, 2022 Results on Nov 16, 2022

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Burning Rock Biotech Limited Provides Revenue Guidance for the Fiscal Year 2022

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Burning Rock Biotech Limited to Report Q2, 2022 Results on Aug 31, 2022

Burning Rock Biotech Limited, Annual General Meeting, Sep 08, 2022

Consensus forecasts updated

Burning Rock Biotech Limited Announces Board Changes

Burning Rock Biotech Limited Launches Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study

Burning Rock Announces Changes to Board Composition

Burning Rock Biotech Limited (NasdaqGM:BNR) announces an Equity Buyback for $10 million worth of its shares.

Burning Rock Biotech Limited Presents Latest Clinical Data from Thunder Study At 2022 ASCO Annual Meeting

Burning Rock Localizes As Investors Grow Impatient

First quarter 2022 earnings: Revenues miss analyst expectations

Burning Rock Biotech Limited Provides Revenue Guidance for the Full Year 2022

Burning Rock Biotech Limited to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus EPS estimates fall by 219%

COO & Director notifies of intention to sell stock

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Burning Rock Biotech Limited to Report Q4, 2021 Results on Mar 22, 2022

Burning Rock Biotech Limited Provides Revenue Guidance for 2021

Third quarter 2021 earnings released

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Second quarter 2021 earnings released: CN¥2.33 loss per share (vs CN¥2.68 loss in 2Q 2020)

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

COO & Director notifies of intention to sell stock

First quarter 2021 earnings released: CN¥1.65 loss per share (vs CN¥3.15 loss in 1Q 2020)

Burning Rock Biotech Limited Reiterates Earnings Guidance for the Full Year 2021

Burning Rock Announces the Launch of China’S First Prospective Pan-Cancer Multi-Omics Early Detection Study